Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 18/20 | 0.84 |
| ▸ | MEN1 | O00255 | 6/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.84 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.84 |
| ▸ | CASP1 | P29466 | 3/20 | 0.84 |
| ▸ | CASP7 | P55210 | 3/20 | 0.84 |
| ▸ | HBB | P68871 | 3/20 | 0.84 |
| ▸ | MAPT | P10636 | 3/20 | 0.84 |
| ▸ | USP2 | O75604 | 2/20 | 0.84 |
| ▸ | LMNA | P02545 | 2/20 | 0.84 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.84 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.84 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.84 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.84 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.84 |
| ▸ | TOP2A | P11388 | 1/20 | 0.84 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.84 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27781717 | 1.00 | TOP1 (0.84) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL27477913 | 0.94 | TOP1 (0.85) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL3376452 | 0.94 | TOP1 (0.85) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL27595325 | 0.94 | TOP1 (0.81) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL23432496 | 0.94 | TOP1 (0.81) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL4289849 | 0.93 | TOP1 (0.82) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL3377674 | 0.93 | TOP1 (0.82) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL30884751 | 0.93 | TOP1 (0.82) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL27595214 | 0.92 | TOP1 (0.79) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL27504832 | 0.92 | TOP1 (0.81) | TOP1MEN1KMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139899-B1 | CRYSTALLINE FORMS OF TOPOTECAN HYDROCHLORIDE AND PROCESSES FOR MAKING THE SAME | SCINOPHARM TAIWAN LTD (TW) | 2016-10-19 | — | — | EP | disclosed |
| US-8013158-B2 | (10-[(dimethyl amino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-ine-3,14(4H,12H)dione hydrochloride); characterized by their X-ray powder diffraction patterns and their IR spectra | SCINOPHARM TAIWAN LTD. (TW) | 2011-09-06 | — | — | US | disclosed |
| US-7977483-B2 | Process for making topotecan | SCINOPHARM TAIWAN, LTD. (TW) | 2011-07-12 | — | — | US | disclosed |
| US-7977483-B2 | Process for making topotecan | SCINOPHARM TAIWAN, LTD. (TW) | 2011-07-12 | — | — | US | disclosed |
| EP-2139899-A1 | CRYSTALLINE FORMS OF TOPOTECAN HYDROCHLORIDE AND PROCESSES FOR MAKING THE SAME | ScinoPharm Taiwan, Ltd. (TW) | 2010-01-06 | — | — | EP | disclosed |
| US-20090221826-A1 | Process for making topotecan | SCINOPHARM TAIWAN, LTD. (TW) | 2009-09-03 | — | — | US | disclosed |
| US-20090221826-A1 | Process for making topotecan | SCINOPHARM TAIWAN, LTD. (TW) | 2009-09-03 | — | — | US | disclosed |
| WO-2008130534-A1 | CRYSTALLINE FORMS OF TOPOTECAN HYDROCHLORIDE AND PROCESSES FOR MAKING THE SAME | SCINOPHARM TAIWAN LTD. (TW) | 2008-10-30 | — | — | WO | disclosed |
| US-20080269493-A1 | Crystalline forms of topotecan hydrochloride and processes for making the same | SCINOPHARM TAIWAN LTD. (TW) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269493-A1 | Crystalline forms of topotecan hydrochloride and processes for making the same | TOP2A, TOP1, TOP2B | TOP1 2/4885MEN1 1030/4885KMT2A 1365/4885 |
| US-20090221826-A1 | Process for making topotecan | TOP2A, TOP1, TOP2B | TOP1 2/4885MEN1 706/4885KMT2A 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.